These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 27823952)

  • 1. Novel findings of secreted cyclophilin A in diabetic nephropathy and its association with renal protection of dipeptidyl peptidase 4 inhibitor.
    Tsai SF; Hsieh CC; Wu MJ; Chen CH; Lin TH; Hsieh M
    Clin Chim Acta; 2016 Dec; 463():181-192. PubMed ID: 27823952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
    Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy.
    Sharkovska Y; Reichetzeder C; Alter M; Tsuprykov O; Bachmann S; Secher T; Klein T; Hocher B
    J Hypertens; 2014 Nov; 32(11):2211-23; discussion 2223. PubMed ID: 25215436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes.
    Spencer NY; Yang Z; Sullivan JC; Klein T; Stanton RC
    PLoS One; 2018; 13(7):e0200249. PubMed ID: 29979777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice.
    Fujii M; Inoguchi T; Maeda Y; Sasaki S; Sawada F; Saito R; Kobayashi K; Sumimoto H; Takayanagi R
    Kidney Int; 2007 Aug; 72(4):473-80. PubMed ID: 17568784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hibiscus sabdariffa polyphenols alleviate insulin resistance and renal epithelial to mesenchymal transition: a novel action mechanism mediated by type 4 dipeptidyl peptidase.
    Peng CH; Yang YS; Chan KC; Wang CJ; Chen ML; Huang CN
    J Agric Food Chem; 2014 Oct; 62(40):9736-43. PubMed ID: 25226384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
    Jung E; Kim J; Ho Kim S; Kim S; Cho MH
    Eur J Pharmacol; 2015 Aug; 761():116-24. PubMed ID: 25977232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment.
    Fujita A; Yoh K; Shimohata H; Morito N; Ojima M; Okamura M; Takahashi S; Yamagata K
    Exp Anim; 2012; 61(1):49-57. PubMed ID: 22293672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice.
    Wang LH; Liu JS; Ning WB; Yuan QJ; Zhang FF; Peng ZZ; Lu MM; Luo RN; Fu X; Hu GY; Wang ZH; Tao LJ
    Pharmacology; 2011; 88(1-2):88-99. PubMed ID: 21847000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.
    Nakashima S; Matsui T; Takeuchi M; Yamagishi SI
    Horm Metab Res; 2014 Sep; 46(10):717-21. PubMed ID: 24710699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.
    Ma M; Hasegawa Y; Koibuchi N; Toyama K; Uekawa K; Nakagawa T; Lin B; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2015 May; 14():54. PubMed ID: 25986579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
    Kanasaki K; Shi S; Kanasaki M; He J; Nagai T; Nakamura Y; Ishigaki Y; Kitada M; Srivastava SP; Koya D
    Diabetes; 2014 Jun; 63(6):2120-31. PubMed ID: 24574044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan attenuates diabetic nephropathy by suppressing oxidative stress in db/db mice.
    Sato-Horiguchi C; Ogawa D; Wada J; Tachibana H; Kodera R; Eguchi J; Nakatsuka A; Terami N; Shikata K; Makino H
    Nephron Exp Nephrol; 2012; 121(3-4):e97-e108. PubMed ID: 23307263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Linagliptin on Structural Changes in the Kidney in Experimental Type 2 Diabetes Mellitus.
    Gavrilova YS; Bgatova NP; Klimontov VV; Ischenko IY; Michurina SV; Myakina NE; Zavyalov EL
    Bull Exp Biol Med; 2016 Aug; 161(4):501-4. PubMed ID: 27591880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gallic acid ameliorates renal functions by inhibiting the activation of p38 MAPK in experimentally induced type 2 diabetic rats and cultured rat proximal tubular epithelial cells.
    Ahad A; Ahsan H; Mujeeb M; Siddiqui WA
    Chem Biol Interact; 2015 Oct; 240():292-303. PubMed ID: 26341651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective effects of incretin-based drugs: A novel pleiotropic effect of dipeptidyl peptidase-4 inhibitor.
    Kodera R; Shikata K
    J Diabetes Investig; 2016 Jan; 7(1):29-31. PubMed ID: 26816598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delineating a role for the mitochondrial permeability transition pore in diabetic kidney disease by targeting cyclophilin D.
    Lindblom RSJ; Higgins GC; Nguyen TV; Arnstein M; Henstridge DC; Granata C; Snelson M; Thallas-Bonke V; Cooper ME; Forbes JM; Coughlan MT
    Clin Sci (Lond); 2020 Jan; 134(2):239-259. PubMed ID: 31943002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
    Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
    Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.